Additionally, a significant proportion of AML patients exhibit elevated levels of B7-H3 on leukemic blasts, making it a promising target antigen for the development of CAR-T therapy specifically directed towards AML38. This evidence concerns the gene CD276 and acute myeloid leukemia.